BIIB059 (Litifilimab) is a medication being studied for its potential to help people with certain types of lupus, specifically subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus. These are conditions where the immune system mistakenly attacks the skin, causing rashes and other symptoms. This medication is being tested to see if it can safely and effectively reduce these symptoms over a long period. It is particularly aimed at people who have not had success with or cannot tolerate traditional treatments like antimalarial drugs. The goal is to find out if this medication can be a reliable option for managing lupus symptoms without causing significant side effects.

Subacute Cutaneous Lupus Erythematosus – This is a form of lupus that primarily affects the skin, causing lesions that are often red, scaly, and can appear in sun-exposed areas. The lesions may be ring-shaped or have a papulosquamous appearance, resembling psoriasis. Over time, these lesions can lead to skin discoloration but typically do not cause scarring. The condition can be triggered or worsened by sun exposure. It is often associated with mild systemic symptoms, such as joint pain or fatigue. The disease can fluctuate, with periods of flare-ups and remission.

Chronic Cutaneous Lupus Erythematosus – This form of lupus is characterized by persistent skin lesions that can lead to scarring. The most common type is discoid lupus erythematosus, which presents as round, red, and scaly patches that can thicken and scar over time. These lesions are typically found on the face, scalp, and ears, and can cause hair loss if they occur on the scalp. The condition is chronic, meaning it can last for a long time and may have periods of activity and inactivity. Sun exposure can exacerbate the lesions. Unlike systemic lupus, this form primarily affects the skin and is less likely to involve internal organs.